T. Rowe Price Investment Management, Inc.
Position in CGON — CG Oncology, Inc.
CIK 1897612
BALTIMORE, MD
Position in CGON
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$470,130,673
+$15,294,746 QoQ
Shares Held
6,616,899
-1.5% QoQ
Ownership
7.46%
of shares outstanding
% of Portfolio
0.31%
of 13F equity value
Holder Rank
#2
of 226 holders
Holding Since
Mar 2024
5 quarters on record
Voting authority
Sole 96%
Shared 0%
None 4%
Common Shares in CGON Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026T. Rowe Price Investment Management, Inc. holds $12,244,164,567 across 51 Biotechnology names. CGON ranks #7 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
6,754,846 | $1,801,652,525 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
5,642,173 | $1,698,463,338 | |
| 3 | CYTK |
Cytokinetics Inc
|
18,718,498 | $1,594,628,844 | |
| 4 | KYMR |
Kymera Therapeutics, Inc.
|
6,257,261 | $717,520,118 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
12,207,450 | $709,619,068 | |
| 6 | DYN |
Dyne Therapeutics, Inc.
|
30,912,287 | $686,561,894 | |
| 7 | CGON |
CG Oncology, Inc.
This page
|
6,616,899 | $470,130,673 | |
| 8 | IMNM |
Immunome Inc.
|
19,676,883 | $416,953,150 |
All Filings in CGON
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $470,130,673 | 6,616,899 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $454,835,927 | 6,720,389 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,737,612 | 41,850 | Shares | Sole | 2026-02-17 | |
| 2024-06-30 | $2,102,435 | 66,596 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $31,112,412 | 708,711 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||